Boryung eying sales of 100 billion won with new antihypertensive agent

Published: 2011-02-24 06:58:00

Updated: 2011-02-24 06:58:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, says it will launch its homegrown antihypertensive drug, Fimasartan, in March as its health insurance price is expected to be settled sooner or later.

The drug marks the 15th new medicine developed by a local drug man...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK